30 April 2020 Clarivate have provided free access to COVID-19 content in their BioWorld suite of news services. Viewers can access general news as well as three critical tables summarising: Vaccines and therapeutics in development Diagnostics on the…
27 April 2020 A wearable smart patch will deliver precision data to help people personalise their diets and reduce their risk of developing lifestyle-related chronic diseases like Type 2 diabetes. The world-first personalised nutrition wearable being developed by…
29 April 2020 Melbourne researchers at the Walter and Eliza Hall Institute have revealed for the first time that males infected with the Toxoplasma parasite can impact their offspring’s brain health and behaviour. Studying mice infected with the common parasite Toxoplasma,…
29 April 2020 Monash University’s Dr James McMahon, an infectious disease expert and hospital clinician at The Alfred and Monash Health, is leading the development of a biobank aimed at cracking the immunity code of COVID-19. The biobank enables…
28 April 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces further positive interim data from its ongoing Phase II TACTI-002 study. The data relates to the…
28 April 2020 Melbourne breast cancer researchers have discovered a new type of immune cell that helps to keep breast tissue healthy by regulating a vital process within mammary ducts – the sites where milk is produced and…
23 April 2020 Australian researchers have made a world-first breakthrough that has the potential to monitor the changes in pH levels and other responses to therapy in stroke and cancer patients. Researchers from Monash University and the Baker…
22 April 2020 RMIT fashion and textiles experts have designed a new style of protective face mask for healthcare workers. The staff and student team has sewn 100 of the prototype masks as part of a Federal Government…
23 April 2020 Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that the last patient has been enrolled and safely dosed for the second cohort of the INSIGHT-004 Phase I clinical…
23 April 2020 PolyNovo is pleased to announce the first use of NovoSorb BTM in Canada. This case was initiated by one of Canada’s leading surgeons who is a key opinion leader in this field. PolyNovo has not…
21 April 2020 PolyNovo is pleased to share the summary of results for the CP-002 Feasibility Study to assess the safety and effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the treatment of severe skin burn injuries. This…
22 April 2020 Melbourne, Australia and Seoul, South Korea: VivaZome Therapeutics Pty Ltd (“VivaZome”) and ToolGen, Inc (“ToolGen”) have announced the extension of a collaborative research project exploring the gene-editing of cells for enhanced exosome production. Under the…